Refining the criteria for sentinel lymph node biopsy in patients with thinner melanoma a roadmap for the future

Cancer

Volumn 116, Issue 6, 2010, Pages 1403-1405

  Messina, Jane L ^a   Sondak, Vernon K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; MEDICAL PRACTICE; MELANOMA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

BIAS (EPIDEMIOLOGY); HUMANS; MELANOMA; NEOPLASM STAGING; PATIENT SELECTION; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 77949396619     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24908     Document Type: Editorial

References (13)

1. Phan GQ, Messina JL, Sondak VK, Zager JS. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control. 2009;16:234-239.
2. Demierre MF, Sabel MS, Margolin KA, Daud AI, Sondak VK. State of the Science 60th Anniversary Review: sixty years of advances in cutaneous melanoma epidemiology, diagnosis and treatment, as reported in the journal Cancer. Cancer. 2008;113:1728-1743.
3. Balch CM, Morton DL, Gershenwald JE, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009;60:872-875.
4. Morton DL, Thompson JF, Cochran AJ, et al. Sentinelnode biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
5. Thomas JM. Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. J Plast Reconstr Aesthet Surg. 2009;62:442-446.
6. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134.
7. Karakousis GC, Gimotty PA, Czerniecki BJ, et al. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN staging biopsy in these patients. Ann Surg Oncol. 2007;14:1596-1603.
8. Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003;21:1326-1331.
9. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143:892-899.
10. Mays M, Martin RCG, Burton A, et al. Should all patients with melanomas between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Cancer. 2009;116:1535-1544.
11. McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86:212-223.
12. Sondak VK, Taylor JMG, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247-258.
13. Chagpar RB, Ross MI, Reintgen DS, et al. Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis. J Surg Res. 2007;143:164-168.